Cardio Diagnostics Holdings, Inc. (CDIO)

0.9052 +0.1758 (+24.10%) At close: 04:00PM EDT

Cardio Diagnostics Holdings, Inc.

311 West Superior Street
Suite 444
Chicago, IL 60654
United States
302 281 2147
https://cardiodiagnosticsinc.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Meeshanthini V. Dogan Ph.D.	Co-Founder, CEO & Director	307.25k	N/A	1989
Ms. Elisa Michael Luqman Esq., J.D., M.B.A.	Chief Financial Officer	275k	N/A	1964
Dr. Robert A. Philibert M.D., Ph.D.	Co-Founder, Chief Medical Officer & Director	N/A	N/A	1962
Mr. Timur Dogan Ph.D.	Chief Technology Officer	N/A	N/A	1988
Ms. Khullani Abdullahi J.D.	Vice President of Revenue & Strategy	N/A	N/A	1984

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Corporate Governance

Cardio Diagnostics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.